De Novo device
ADVIA Centaur Enhanced Liver Fibrosis (ELF)
Siemens Healthcare Diagnostics, Inc. · Prognostic Test For Assessment Of Liver Related Disease Progression (QQB, Class II) · First FDA decision Aug 20, 2021, newest Aug 20, 2021Liver disease and liver cancer
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
Breakthrough-designated
Device trials
0
Naming "ADVIA Centaur Enhanced"
MAUDE reports
5
Brand "ADVIA Centaur Enhanced", since 2015
PubMed studies
0
Mentioning "ADVIA Centaur Enhanced"
AI summary across all sources
Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- ADVIA Centaur Enhanced Liver Fibrosis (ELF)New device typeBreakthroughDe Novo
DEN190056 · Decided Aug 20, 2021 · 603 days after receipt
Device type: Prognostic Test For Assessment Of Liver Related Disease Progression (QQB) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- MolDX: Biomarker Testing in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated SteatohepatitisLocal determinationIn effectL40187Palmetto GBAUpdated Jun 19, 2026
- MolDX: Biomarker Testing in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated SteatohepatitisLocal determinationIn effectL40197Noridian Healthcare Solutions, LLCUpdated Jun 19, 2026
- MolDX: Biomarker Testing in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated SteatohepatitisLocal determinationIn effectL40199CGS Administrators, LLCUpdated Jun 19, 2026
- MolDX: Biomarker Testing in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated SteatohepatitisLocal determinationIn effectL40272WPS Insurance CorporationUpdated Jun 18, 2026
- MolDX: Biomarker Testing for Risk Stratification in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated SteatohepatitisProposed local determinationProposedDL40197Noridian Healthcare Solutions, LLCUpdated Aug 22, 2025
- MolDX: Biomarker Testing for Risk Stratification in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated SteatohepatitisProposed local determinationProposedDL40199CGS Administrators, LLCUpdated Aug 21, 2025
- MolDX: Biomarker Testing for Risk Stratification in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated SteatohepatitisProposed local determinationProposedDL40272WPS Insurance CorporationUpdated Aug 20, 2025
- MolDX: Biomarker Testing for Risk Stratification in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated SteatohepatitisProposed local determinationProposedDL40187Palmetto GBAUpdated Aug 18, 2025
Clinical trials
Device studies on ClinicalTrials.gov that name "ADVIA Centaur Enhanced", any status and sponsor, newest update first.
No registered device study names "ADVIA Centaur Enhanced".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "ADVIA Centaur Enhanced", and for the whole product code for context.
This brand
5 reports: 5 malfunction, 0 injury, 0 death
Whole product code QQB
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "ADVIA Centaur Enhanced"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.